These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 2574921)
1. [Prevention of recurrence of peptic ulcers]. Fölsch UR Verh Dtsch Ges Inn Med; 1989; 95():319-22. PubMed ID: 2574921 [No Abstract] [Full Text] [Related]
2. [Experimental study of Dolispan in the therapy of peptic ulcer]. Manolov P; Todorov S Eksp Med Morfol; 1974; 13(1):36-9. PubMed ID: 4151718 [No Abstract] [Full Text] [Related]
3. The medical therapy of peptic ulcer. Bevan G Postgrad Med J; 1975; 51(5 Suppl):14-8. PubMed ID: 7780 [No Abstract] [Full Text] [Related]
4. Maintenance treatment with H2 receptor antagonists in patients with peptic ulcer disease: reduces morbidity in a significant minority of patients. Wormsley KG BMJ; 1988 Nov; 297(6660):1392, 1394. PubMed ID: 2905897 [No Abstract] [Full Text] [Related]
6. [H1 and H2 histamine antagonists. Principles and rules of use]. Perault MC; Vandel B Rev Prat; 1996 Jun; 46(12):1547-50. PubMed ID: 8881170 [No Abstract] [Full Text] [Related]
7. [Clinical and radiographical study on the effects of the treatment of peptic ulcer with a new antacid-antiulcer agent]. Piro E; Florio F; Tripodi R Clin Ter; 1970 May; 53(4):323-48. PubMed ID: 4394193 [No Abstract] [Full Text] [Related]
8. [New views on the physiopathology of peptic ulcer]. Ottenjann R MMW Munch Med Wochenschr; 1974 Feb; 116(5):181-4. PubMed ID: 4149847 [No Abstract] [Full Text] [Related]
9. [Histamine as the principal pathogenetic factor in gastroduodenal ulcer. Research priorities]. Businco L Minerva Med; 1980 Sep; 71(31):2193-7. PubMed ID: 6158718 [TBL] [Abstract][Full Text] [Related]
10. [Therapeutic effect of a new antisecretory and anti-acid drug]. Galli L; Bissi A Rev Bras Gastroenterol; 1967; 19(3):43-9. PubMed ID: 4387428 [No Abstract] [Full Text] [Related]
11. Maintenance treatment with H2 receptor antagonists in patients with peptic ulcer disease: rarely justified in terms of cost or patient benefit. Howden CW BMJ; 1988 Nov; 297(6660):1393-4. PubMed ID: 2905898 [TBL] [Abstract][Full Text] [Related]
12. [Treatment of ulcer with a new antacid-antisecretive-antispastic combination]. Castellazzi V; Marenco G; Ghibaudi D Clin Ter; 1969 Apr; 49(1):47-61. PubMed ID: 4396961 [No Abstract] [Full Text] [Related]
13. [Effects of the antihistaminic alpha-methylbenzhydril-2-dimethylaminoethylester hydrochloride (alfadryl) in gastrointestinal ulcers]. KOHOUT J Cas Lek Cesk; 1958 Jan; 97(4):114-7. PubMed ID: 13511416 [No Abstract] [Full Text] [Related]
14. [Clinical trial of a new antacid-antiulcer preparation]. Betti M Minerva Med; 1967 Aug; 58(69):2927-34. PubMed ID: 4383470 [No Abstract] [Full Text] [Related]
15. Role of protective drugs in the prevention of ulcer relapse. Ota S; Terano A J Gastroenterol; 1994 Jul; 29 Suppl 7():139-40. PubMed ID: 7921147 [TBL] [Abstract][Full Text] [Related]